Teva disposes of womens health businesses to CVC Capital Partners Fund VI and to Foundation Consumer Healthcare.

Teva Pharmaceutical Industries Ltd.,announced it has entered into two agreements to sell the remaining assets of its specialty global women�s health business for $1.38 billion. Proceeds from these sales, combined with proceeds from the recently announced sale of ParaGard total $2.48 billion and will be used by Teva to progress repayment of term loan debt. Teva has entered into a definitive agreement under which CVC Capital Partners Fund VI will acquire a portfolio of products within its global women�s health business across contraception, fertility, menopause and osteoporosis for $703 million in cash. The portfolio of products, which is marketed and sold outside of the U.S., includes Ovaleap, Zoely, Seasonique, Colpotrophine, Actonel and additional products. Combined annual net sales of Ovaleap, Zoely, Seasonique, Colpotrophine, Actonel and additional products within this portfolio for the full year 2016 were $258 million. Teva has also entered into a definitive agreement under which Foundation Consumer Healthcare will acquire Plan B One-Step and Teva�s value brands of emergency contraception, Take Action, Aftera�, and Next Choice One Dose for $675 million in cash. Combined annual net sales of Plan B One-Step, Take Action, Aftera, and Next Choice One Dose� for the full year 2016 were $140 million.